CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal of ...

Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut transcatheter aortic valve replacement (TAVR) system in low-risk aortic stenosis ...

Patients with severe aortic stenosis had comparable rates of death or disabling stroke, but the lead investigator cautions against an 'irrational' rush to move to younger patients ahead of the data.

Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter aortic valve replacement (TAVR) had similar rates of death or disabling ...

Data shows, versus surgery, the Evolut™ transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years ...

Data shows, versus surgery, the Evolut transcatheter aortic valve replacement, TAVR, system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve ...

Please provide your email address to receive an email when new articles are posted on . At 5 years, there was no difference in death or disabling stroke between transcatheter aortic valve ...

Opens in a new tab or window CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk ...